AI Automated Translation.

Font Size

Share

iNtRON Biotech in talks with global pharmaceutical companies on partnerships for pHyal20 and SAL200

iNtRON Biotech in talks with global pharmaceutical companies on partnerships for pHyal20 and SAL200

INtRON Biotechnology said on Nov. 19 that it has begun discussions on a material transfer agreement (MTA) for its subcutaneous (SC) drug delivery platform, pHyal20, with overseas companies, including global pharmaceutical firms.

The biotechnology drug developer said it held partnership discussions with multiple global pharmaceutical and biotech companies after participating in BIO-Europe 2026, Europe's largest biotechnology partnering event.

At the event, iNtRON Biotech held partnering meetings with global companies, sharing preliminary materials in advance. Several companies reportedly expressed interest in pHyal20, its next-generation subcutaneous drug delivery platform.

An official from iNtRON Biotech said, "Multiple overseas companies developing plasma-derived therapies, biosimilars (replica biopharmaceuticals), and antibody drugs paid attention to pHyal20's enzyme activity and stability, manufacturing costs based on E. coli fermentation, and patent freedom-to-operate (FTO)."

The official added, "We have begun negotiating additional MTA signings with these companies to conduct feasibility studies evaluating the validity of combining [pHyal20] with actual therapeutic candidate molecules."

It is also reported that Intron Bio has conducted discussions on confidentiality agreements (CDAs), technology transfer, and joint development with multiple pharmaceutical companies regarding 'SAL200,' a treatment candidate for multidrug-resistant bacterial infections, commonly known as superbugs.

The negotiations are reportedly being detailed based on data for severe infectious diseases such as endocarditis, focusing on its endolysin-based mechanism of action, which differs from existing antibiotics, and the status of preparations to enter Phase 2b clinical trials with the U.S. Food and Drug Administration (FDA).

Intron Bio is promoting global technology transfer of its core assets, led by SAL200 and pHyal20. Following an MTA signing for 'pHyal20' with a European-based global biopharmaceutical company last month, the company has consecutively participated in the European Society for Medical Oncology (ESMO 2026) and BIO-Europe, expanding its global connections.

An Intron Bio official said, "Through this BIO-Europe, we confirmed the potential of pHyal20 as a platform and the global market potential of assets such as SAL200." The official added, "We will swiftly conclude subsequent CDA and MTA signing negotiations so that discussions on joint research and technology transfer can continue."

"This article was translated using AI and may differ slightly from the original."